PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Novartis AG (NVS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US66987V1098

CUSIP

66987V109

Sector

Healthcare

IPO Date

Nov 18, 1991

Highlights

Market Cap

$209.76B

EPS (TTM)

$5.73

PE Ratio

18.31

PEG Ratio

3.12

Total Revenue (TTM)

$49.29B

Gross Profit (TTM)

$36.69B

EBITDA (TTM)

$19.83B

Year Range

$90.25 - $120.92

Target Price

$117.28

Short %

0.24%

Short Ratio

4.28

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
NVS vs. NVO NVS vs. KO NVS vs. ENB NVS vs. GSK NVS vs. AMT NVS vs. PG NVS vs. SPG NVS vs. EQNR NVS vs. O NVS vs. VOO
Popular comparisons:
NVS vs. NVO NVS vs. KO NVS vs. ENB NVS vs. GSK NVS vs. AMT NVS vs. PG NVS vs. SPG NVS vs. EQNR NVS vs. O NVS vs. VOO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Novartis AG, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


300.00%400.00%500.00%600.00%700.00%800.00%JuneJulyAugustSeptemberOctoberNovember
687.25%
317.00%
NVS (Novartis AG)
Benchmark (^GSPC)

Returns By Period

Novartis AG had a return of 5.97% year-to-date (YTD) and 13.75% in the last 12 months. Over the past 10 years, Novartis AG had an annualized return of 6.63%, while the S&P 500 had an annualized return of 11.11%, indicating that Novartis AG did not perform as well as the benchmark.


NVS

YTD

5.97%

1M

-11.59%

6M

0.48%

1Y

13.75%

5Y (annualized)

8.25%

10Y (annualized)

6.63%

^GSPC (Benchmark)

YTD

23.08%

1M

0.10%

6M

10.70%

1Y

30.05%

5Y (annualized)

13.52%

10Y (annualized)

11.11%

Monthly Returns

The table below presents the monthly returns of NVS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20242.48%-2.42%-0.54%0.41%6.18%3.23%4.72%8.44%-4.86%-5.76%5.97%
2023-0.11%-7.17%14.40%11.49%-6.16%4.84%3.95%-4.21%1.37%-2.91%4.62%3.14%23.03%
2022-0.64%0.63%4.78%0.32%3.31%-7.05%1.54%-6.19%-5.60%6.74%10.39%1.30%8.32%
2021-4.19%-5.04%3.73%-0.28%3.68%3.24%1.26%-0.00%-11.48%1.20%-3.70%9.75%-3.43%
2020-0.19%-11.16%1.98%2.77%3.19%-0.10%-5.95%4.77%1.05%-10.21%16.33%3.96%3.56%
20191.99%4.24%9.04%-3.26%4.15%6.62%0.30%-1.61%-3.56%0.62%5.56%2.59%29.14%
20187.27%-7.45%0.81%-5.15%-2.83%1.37%11.07%-1.06%3.79%1.51%4.65%-6.25%6.22%
20171.48%5.75%-1.27%3.72%6.15%2.08%2.07%-1.07%1.85%-3.81%3.90%-2.14%19.77%
2016-9.38%-4.98%1.87%4.87%4.66%3.77%0.91%-5.39%0.24%-10.06%-3.18%5.93%-11.80%
20155.12%5.13%-0.78%3.23%0.91%-4.27%5.50%-6.29%-5.45%-1.62%-5.74%0.94%-4.33%
2014-1.63%9.00%2.21%2.26%3.59%0.52%-3.97%3.34%4.78%-1.53%4.27%-4.13%19.45%
20137.14%4.05%5.07%3.54%-2.71%-1.46%1.27%1.91%5.11%1.10%2.02%1.59%32.17%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of NVS is 66, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of NVS is 6666
Combined Rank
The Sharpe Ratio Rank of NVS is 6969
Sharpe Ratio Rank
The Sortino Ratio Rank of NVS is 6060
Sortino Ratio Rank
The Omega Ratio Rank of NVS is 6060
Omega Ratio Rank
The Calmar Ratio Rank of NVS is 7575
Calmar Ratio Rank
The Martin Ratio Rank of NVS is 6767
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Novartis AG (NVS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for NVS, currently valued at 0.85, compared to the broader market-4.00-2.000.002.000.852.48
The chart of Sortino ratio for NVS, currently valued at 1.22, compared to the broader market-4.00-2.000.002.004.001.223.33
The chart of Omega ratio for NVS, currently valued at 1.16, compared to the broader market0.501.001.502.001.161.46
The chart of Calmar ratio for NVS, currently valued at 0.95, compared to the broader market0.002.004.006.000.953.58
The chart of Martin ratio for NVS, currently valued at 2.76, compared to the broader market0.0010.0020.0030.002.7615.96
NVS
^GSPC

The current Novartis AG Sharpe ratio is 0.85. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Novartis AG with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio1.001.502.002.503.003.50JuneJulyAugustSeptemberOctoberNovember
0.85
2.48
NVS (Novartis AG)
Benchmark (^GSPC)

Dividends

Dividend History

Novartis AG provided a 3.66% dividend yield over the last twelve months, with an annual payout of $3.78 per share.


2.80%3.00%3.20%3.40%3.60%3.80%4.00%$0.00$0.50$1.00$1.50$2.00$2.50$3.00$3.5020132014201520162017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM20232022202120202019201820172016201520142013
Dividend$3.78$3.47$3.36$3.38$3.04$2.57$2.67$2.46$2.47$2.52$2.44$2.27

Dividend yield

3.66%3.44%3.91%4.08%3.40%2.87%3.72%3.50%4.06%3.51%3.14%3.37%

Monthly Dividends

The table displays the monthly dividend distributions for Novartis AG. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.00$0.00$3.78$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.78
2023$0.00$0.00$3.47$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.47
2022$0.00$0.00$3.36$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.36
2021$0.00$0.00$3.38$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.38
2020$0.00$0.00$3.04$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.04
2019$0.00$0.00$2.57$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.57
2018$0.00$0.00$2.67$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.67
2017$0.00$0.00$2.46$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.46
2016$0.00$2.47$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.47
2015$0.00$0.00$2.52$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.52
2014$0.00$2.44$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.44
2013$2.27$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$2.27

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%3.7%
Novartis AG has a dividend yield of 3.66%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%51.3%
Novartis AG has a payout ratio of 51.32%, which is quite average when compared to the overall market. This suggests that Novartis AG strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-15.00%-10.00%-5.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-14.75%
-2.18%
NVS (Novartis AG)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Novartis AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Novartis AG was 41.72%, occurring on Mar 3, 2009. Recovery took 387 trading sessions.

The current Novartis AG drawdown is 14.75%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-41.72%Aug 5, 2008145Mar 3, 2009387Sep 14, 2010532
-33.64%Jul 21, 2015352Dec 8, 2016566Mar 13, 2019918
-25.88%Feb 13, 202027Mar 23, 2020207Jan 15, 2021234
-25.66%Jan 4, 2001130Jul 11, 2001240Jun 28, 2002370
-22.2%Jul 1, 200214Jul 19, 2002347Dec 3, 2003361

Volatility

Volatility Chart

The current Novartis AG volatility is 5.96%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%3.00%4.00%5.00%6.00%7.00%JuneJulyAugustSeptemberOctoberNovember
5.96%
4.06%
NVS (Novartis AG)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Novartis AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Novartis AG compared to its peers in the Drug Manufacturers - General industry.


PE Ratio
200.0400.0600.0800.01,000.018.3
The chart displays the price to earnings (P/E) ratio for NVS in comparison to other companies of the Drug Manufacturers - General industry. Currently, NVS has a PE value of 18.3. This PE value is considered to be low compared to the rest of the industry.
PEG Ratio
10.020.030.03.1
The chart displays the price to earnings to growth (PEG) ratio for NVS in comparison to other companies of the Drug Manufacturers - General industry. Currently, NVS has a PEG value of 3.1. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Novartis AG.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items